NKTR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Nektar Therapeutics (NKTR) is not a strong buy at the moment for a beginner investor with a long-term strategy. While there are positive catalysts such as strong analyst ratings and potential product pipeline growth, the financial performance is weak, hedge funds are selling, and the technical indicators show mixed signals. Given the investor's impatience and unwillingness to wait for optimal entry points, this stock does not currently present a compelling opportunity.
The stock shows mixed technical signals. The MACD is below 0 and negatively contracting, indicating bearish momentum. RSI is neutral at 67.863, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support and resistance levels are at Pivot: 70.092, R1: 74.359, and S1: 65.825. However, the pre-market price is down by -1.23%, suggesting short-term weakness.
Strong analyst ratings with multiple price target increases (e.g., B. Riley raised to $150, H.C. Wainwright raised to $165). Positive updates on Rezpeg's efficacy and durability in clinical trials, with potential peak sales of $2B. Removal of equity financing overhang and compelling Phase 2b results for REZOLVE-AD.
Hedge funds are selling heavily, with a 1229.84% increase in selling activity last quarter. Financial performance is weak, with revenue down -51.13% YoY, net income down -4.14% YoY, and EPS down -29.70% YoY. No recent news or congress trading data to provide additional positive sentiment.
The company's financials for 2025/Q3 show significant declines: Revenue dropped to $11.79M (-51.13% YoY), Net Income dropped to -$35.52M (-4.14% YoY), and EPS dropped to -1.87 (-29.70% YoY). However, gross margin improved to 100% (+22.52% YoY), indicating cost efficiency despite declining revenues.
Analysts are bullish on NKTR, with multiple upgrades and price target increases. B. Riley raised the target to $150, H.C. Wainwright to $165, and BTIG to $151. Analysts cite strong clinical data for Rezpeg and its potential to capture market share in atopic dermatitis and alopecia areata. However, the stock's recent performance and financials do not fully align with these optimistic projections.
